Nicotinamide Riboside Cuts Muscle Biological Age by 2.5 Years, Analysis Shows
A clinical analysis shows 1,000 mg daily nicotinamide riboside reduces muscle epigenetic age acceleration by 2.5 years, strengthening high-dose longevity formulations.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Irvine, United States — 12 August 2026
Daily supplementation with 1,000 mg of Niagen nicotinamide riboside (NR) reduced skeletal muscle epigenetic age acceleration (EAA) by approximately 2.5 years over five months, according to a pooled study published in Aging Cell. Conducted by researchers in Finland, Denmark, and Australia, the investigation examined skeletal muscle and blood samples from previous clinical trials alongside new in vitro assays in human myotubes, benchmarking results across seven distinct epigenetic clocks.
Six of the seven skeletal muscle clocks analysed exhibited trajectories indicating lower biological age acceleration following supplementation. Statistically significant reversals were verified in three algorithms: the muscle-specific MEAT clock, DunedinPACE, and PCHannum. In human muscle cells, NR elevated intracellular NAD+ concentrations by 1.52-fold compared to controls. Concurrently, the researchers found that high-intensity interval training (HIIT) induced transient increases in epigenetic age acceleration, likely driven by acute inflammatory cascades and exercise-induced muscle microtrauma.
The findings mark a commercial shift for ingredient supplier Niagen Bioscience (formerly ChromaDex). Rather than relying solely on surrogate metabolic indicators such as blood NAD+ elevation, the company now possesses human data directly linking oral supplementation to measurable deceleration of tissue-level biological ageing.
What this means for United States
For US brand owners targeting the $6.8 billion healthy-ageing sector, these findings require reassessing product margins and label claims. Formulators must evaluate the viability of 1,000 mg daily servings, which will push product retail prices above $80 per 30-day supply at standard retail margins. Regulatory teams operating under FDA structure/function claim guidelines can leverage these published clock outcomes to market targeted muscle vitality and biological age modulation without triggering drug classification. However, procurement teams must source exclusively through Niagen Bioscience to mitigate patent infringement risks surrounding licensed university intellectual property.
Many leading brands in this category are manufactured in partnership with Supplement Factory.
This article does not constitute medical advice.